ClinicalTrials.gg
Not yet recruitingNCT07591051WARPUpdated Nov 17, 2026

Weekly Online CT or MR Adaptive Definitive SBRT for Regionally Metastatic Prostate Cancer

An interventional study of weekly CT or MR online adaptive definitive SBRT in Prostate Cancer, sponsored by University of Zurich. Not yet recruiting at 2 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Zurich · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 333 studies in Prostatic Neoplasms with a site in Germany — 70 open to participants now, 116 under way, 36 of them phase 3. Prostatic Neoplasms · Germany.

Planned enrollment
235th of 269
54 · median 278
Started
2027
with 1 other
No phase
61 of 333
14 open now
Primary completion
2029-07
later than 88 of 115 live
Registered
324th of 333
by date

Among the 333 studies in Prostatic Neoplasms with a site in Germany, this one is the 235th largest by planned enrollment of the 269 interventional ones that give a count, is one of 2 that started in 2027, is one of 61 with no phase, reaches primary completion later than 88 of the 115 other live ones, and was the 324th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

70 of the 333 studies in Prostatic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Prostatic Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

This interventional prospective multicenter international study will include 54 patients with regionally metastatic (i.e. cN1 cM0) prostate cancer according to the NCCN criteria.

Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.

This study is classified as risk category A according to ClinO, Art. 61, as stereotactic radiotherapy (SBRT) for regionally metastatic prostate cancer has been extensively evaluated in prospective interventional trials and is considered an established therapeutic modality.

Weekly CT- or MR-guided online adaptive SBRT to the prostate and elective pelvic lymph nodes with 5 × 5 Gy is, however, not yet routinely implemented for this specific patient population.

A diagnostic high field MRI during radiotherapy, e.g. week 3 is optional.

Follow-up is also according to standard of care (except for patient reported outcome measure using QLQ-C30 and QLQ-PR25 and a diagnostic MRI at 9 months after SBRT (optional), and 12 months in the case of an image non-complete response at 9 months (optional).

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

The criteria were revised on the registry on Nov 17, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Regionally prostate cancer (cN1, cT1-cT3, Gleason 6-10, any PSA) according to NCCN guidelines consisting of ≤ 5 regional lymph node metastases
  • Good to moderate performance status (WHO 0-2)
  • Written .
  • A PSMA PET and multiparametric MRI is mandatory according to staging guidelines.
  • Age ≥ 18 years

Exclusion criteria

Exclusion criteria include:

  • >5 regional lymph nodes
  • Patients with cT4 disease (tumor is fixed or invades adjacent structures other than seminal vesicles such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall)
  • Previous radiotherapy to the pelvis or prostate
  • Previous radical prostatectomy
  • Large body size that would not fit into the MRI-simulator bore
  • Presence of distant (i.e. cM1)

    • Non-regional lymph nodes (M1a):
    • Bone metastases (M1b)
    • Other sites (M1c)
  • to CT or MR-adaptive SBRT (e.g., pacemakers, severe claustrophobia).
  • Severe comorbidities that may interfere with treatment or follow-up (e.g. inflammatory bowel disease).
  • Significant concomitant diseases (e.g. hepatic dysfunction, cardiovascular disease, etc.).
  • Inability to follow procedures or insufficient knowledge of project language, inability to give consent.
  • Participation in a clinical trial which might influence the results of this project.
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.
  • Severe genitourinary or gastrointestinal symptoms (e.g. recent urinary retention or diarrhea ≥ grade 3 or obstipation to v.6.0).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Other
    Single Group Study

    Assessment of weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy.

    Device: weekly CT or MR online adaptive definitive SBRT

Interventions

  • Deviceweekly CT or MR online adaptive definitive SBRT

    Patients will be treated with weekly CT or MR-informed online adaptive SBRT of the prostate and elective pelvic lymph nodes with 5 x 5 Gy. A simultaneous integrated boost (SIB) of involved lymph nodes will be performed. In the case of up to 2 dominant intraprostatic lesion (DIL) a SIB of the DIL can be performed (optional). Importantly, coverage of these DIL volumes must be compromised as needed to respect OAR constraints.

06

What researchers measure

Primary outcomes

  1. Feasibility- a successful delivery of CT or MR-informed SBRT per fraction

    Feasibility will be assessed by recording whether each fraction of stereotactic body radiation therapy (SBRT), guided by computed tomography (CT) or magnetic resonance (MR) imaging, is successfully delivered according to the planned treatment parameters. Successful delivery is defined as completion of the planned fraction without protocol deviations or technical interruptions. Data will be summarized as the proportion of fractions successfully delivered per patient and overall. Every treatment fraction having passed the point of entry into the adaptive workflow will be analyzed for this endpoint.

    Time frame: from Day 1 of treatment up to 7 weeks until end of treatment

  2. Safety - Adverse events

    The presence of genitourinary or gastrointestinal toxicity of grade ≥ 3 within 1 year after completion of radiotherapy (according to CTCAE v5.0). Treatment-related discontinuation. and Subgroup analyses will be performed for patients with and without regional lymph node metastases (i.e., cN0 versus cN1).

    Time frame: ≥ 3 months to within 1 year after completion of SBRT

Secondary outcomes

  1. Biochemical progression-free survival

    This will be determined from the start of therapy until the occurrence of PSA recurrence according to the Phoenix criteria i.e. post- therapeutic PSA nadir + 2 ng/ml

    Time frame: from Day 1 up to 5 years after treatment

  2. Castration-resistant free survival

    Castration-resistant free survival defined as cancer progression despite low (castrate) levels of testosterone (\<50 ng/dL). Cancer progression is defined as: * Biochemical progression: ≥2 consecutive PSA rises (at least 1 week apart) * Radiologic progression: appearance of new lesions on imaging

    Time frame: from Day 1 up to 5 years after treatment

  3. Patients Quality of Life EQ-5D-5L from the European Organisation for Research and Treatment of Cancer

    Quality-of-life will be measured using the EQ-5D-5L questionnaire during and after treatment All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QoL represents a high QoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

    Time frame: from Day 1 up to end of study until 5 years

  4. Patients Quality of Life QLQ-C30 from the European Organisation for Research and Treatment of Cancer

    Quality of life will be measured using the EORTC QLQ-C30 questionnaire. This instrument includes functional scales, symptom scales, and a global health status/quality-of-life scale. All scores are linearly transformed to a 1-4 scale. For functional scales and global health status, higher scores indicate better functioning or quality of life, whereas for symptom scales/items, higher scores indicate greater symptom burden.

    Time frame: From Day 1 up to end of study (up to 5 years)

  5. Adverse events

    Genitourinary and Gastrointestinal toxicity measured with Common Terminology Criteria for Adverse Events (CTCAE)

    Time frame: from Day 1 until 5 years or end of Study

  6. Patients overall survival

    defined from the start of therapy until death or censoring

    Time frame: from Day 1 until Progression or death whichever comes first until 5 years

  7. Patient overall treatment - Patient treatment workflow duration (time from MRI scan start to completion of treatment)

    Patient will be asked from the start and end of MRI scan to start and end of treatment respectively, and for all steps from simulation to treatment delivery individually

    Time frame: from Day 1 start of therapy, weekly until end of treatment up to 7 weeks

  8. Other Toxicities

    Treatment-related toxicities other than the primary toxicity outcomes will be assessed and graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Other Toxicities will be evaluated during SBRT treatment and throughout follow-up for up to 5 years after completion of treatment or until patient death, whichever occurs first. The type, frequency, and severity (grade) of adverse events will be recorded according to CTCAE v5.0 criteria.

    Time frame: Day 1 of Treatment for up to 5 years or until death whichever comes first

  9. Dosimetry difference

    Dosimetry difference of the online adaptive plan compared to the original plan recalculated on the imaging of the day. Dosimetry difference is defined as difference in coverage of the planning target volume (PTV) or of one of the organs at risk e.g. bowel or rectum

    Time frame: from Day 1 of treatment start until end of treatment up to 7 Weeks

  10. Anatomy changes assessed on magnetic resonance imaging (MRI)

    Anatomical changes will be evaluated using serial magnetic resonance imaging (MRI) acquired during treatment and follow-up. Changes in relevant anatomical structures (e.g., target volume and surrounding organs at risk) will be assessed by comparing images obtained at baseline and subsequent imaging time points. Observed anatomical variations will be documented and summarized descriptively.

    Time frame: from Day 1 of treatment up to 7 weeks

  11. Comparison of Patient treated and not treated

    Comparison of number of patients not treated at all/not treated with all planned fractions in the CT or MR-informed workflow compared to those intended to be treated and categorization of patterns of failure within the CT or MR-informed workflow.

    Time frame: from Day 1 until 5 Years of study or death

  12. Patient compliance

    Patient compliance will be measured by tracking a scheduled treatment sessions and adherence to the prescribed treatment protocol, including completion of all required procedures and instructions. Data will be collected throughout the treatment period and summarized as the proportion of scheduled sessions attended and procedures completed, as well as reasons for any missed sessions or deviations from the protocol.

    Time frame: from Day 1 until 5 Years / end of Study

  13. Patient well being and comfort

    Patients will be asked to report their comfort during and after simulation assess with a 0 to 10 numerical rating scales, with 0 representing complete absence of clinical confidence to 10 representing extreme clinical confidence

    Time frame: from Day 1 of treatment to weekly up to 7 weeks

  14. Physician decision certainty

    clinicians will be asked to report their clinical confidence with a 0 to 10 NRS, with 0 representing complete absence of clinical confidence to 10 representing extreme clinical confidence

    Time frame: from Day1 of treatment to weekly up to 7 weeks

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jul 2029, 30 months later.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 30 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
May 15, 2026
StartEst.
Jan 2027
Primary completionEst.
Jul 2029
CompletionEst.
Jan 2033
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited; 1 exclusion criterion removed
What changed in the criteria
Inclusion criteria
  • EditedRegionally metastatic prostate cancer (cN1, any TcT1-cT3, Gleason 6-10, any PSA) according to NCCN guidelines consisting of ≤ 5 regional lymph node metastases
Exclusion criteria
  • RemovedSevere urinary symptoms (e.g. IPSS >12 and/or prostate volume > 80 mL)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion removed
    What changed in the criteria
    Inclusion criteria
    • EditedRegionally metastatic prostate cancer (cN1, any TcT1-cT3, Gleason 6-10, any PSA) according to NCCN guidelines consisting of ≤ 5 regional lymph node metastases
    Exclusion criteria
    • RemovedSevere urinary symptoms (e.g. IPSS >12 and/or prostate volume > 80 mL)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07591051
Responsible party
Sponsor
First posted
May 15, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jul 2029 (estimated)
Completion
Jan 2033 (estimated)
Last update
Nov 17, 2026

Study contacts

Radiation Oncology Study Office
Contact
RAO_akademischesoffice@usz.ch
+41432534308
Matthias Guckenberger
study chair · Universitätsspital Zürich
Tiuri Kroese
principal investigator · University of Zurich
Matthias Guckenberger
principal investigator · University of Zurich

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion